Lumateperone vs ZIPRASIDONE

Compare Lumateperone (Caplyta) and ZIPRASIDONE (ziprasidone) — clinical data, side effects, and patient experiences.

Lumateperone

Caplyta · Atypical Antipsychotic

How it works

Simultaneously modulates serotonin, dopamine, and glutamate neurotransmission via 5-HT2A antagonism, D2 partial agonism, and SERT inhibition.

Approved for

Schizophrenia

Bipolar Depression

OralTablet

ZIPRASIDONE

ziprasidone, Geodon · Atypical Antipsychotic

How it works

12.1 Mechanism of Action The mechanism of action of ziprasidone in the treatment of the listed indications could be mediated through a combination of dopamine type 2 (D 2 ) and ser...

Approved for

1 INDICATIONS AND USAGE Ziprasidone capsules are indicated for the treatment of schizophrenia

as monotherapy for the acute treatment of bipolar manic or mixed episodes

and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. When deciding among the alternative treatments available for the condition needing treatment

a potentially fatal polymorphic ventricular tachycardia

OralTablet

Quick Comparison

LumateperoneZIPRASIDONE

Drug Class

Atypical Antipsychotic

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

Lumateperone

Dizziness

>10%

Nausea

>10%

Headache

1-10%

Drowsiness

1-10%

Drug Not Working

1-10%

Anxiety

1-10%

Insomnia

0.1-1%

Fatigue

0.1-1%

ZIPRASIDONE

Drug Not Working

>10%

Weight Gain

1-10%

Anxiety

1-10%

Insomnia

1-10%

Depression

1-10%

Drowsiness

1-10%

Fatigue

1-10%

Tremor

1-10%

FDA Warnings

Lumateperone

No specific warnings

ZIPRASIDONE

5 WARNINGS AND PRECAUTIONS Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse reactions (e
3) Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone
4) Neuroleptic Malignant Syndrome (NMS) : Potentially fatal symptom complex has been reported with antipsychotic drugs
DRESS and other Severe Cutaneous Adverse Reactions (SCAR) are sometimes fatal

Clinical Trial Data

No head-to-head clinical studies found for Lumateperone vs ZIPRASIDONE.

Lumateperone vs ZIPRASIDONE: What You Should Know

Key Differences

Both Lumateperone and ZIPRASIDONE belong to the Atypical Antipsychotic class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients.

Safety Considerations

ZIPRASIDONE carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

OLANZAPINE vs ZIPRASIDONE→LURASIDONE HYDROCHLORIDE vs ZIPRASIDONE→PALIPERIDONE vs ZIPRASIDONE→ARIPIPRAZOLE vs ZIPRASIDONE→RISPERIDONE vs ZIPRASIDONE→ARIPIPRAZOLE ORAL vs ZIPRASIDONE→

Loading comparison data...

Lumateperone vs ZIPRASIDONE

Compare Lumateperone (Caplyta) and ZIPRASIDONE (ziprasidone) — clinical data, side effects, and patient experiences.

Lumateperone

Caplyta · Atypical Antipsychotic

How it works

Simultaneously modulates serotonin, dopamine, and glutamate neurotransmission via 5-HT2A antagonism, D2 partial agonism, and SERT inhibition.

Approved for

Schizophrenia

Bipolar Depression

OralTablet

ZIPRASIDONE

ziprasidone, Geodon · Atypical Antipsychotic

How it works

12.1 Mechanism of Action The mechanism of action of ziprasidone in the treatment of the listed indications could be mediated through a combination of dopamine type 2 (D 2 ) and ser...

Approved for

1 INDICATIONS AND USAGE Ziprasidone capsules are indicated for the treatment of schizophrenia

as monotherapy for the acute treatment of bipolar manic or mixed episodes

and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. When deciding among the alternative treatments available for the condition needing treatment

a potentially fatal polymorphic ventricular tachycardia

OralTablet

Quick Comparison

LumateperoneZIPRASIDONE

Drug Class

Atypical Antipsychotic

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

Lumateperone

Dizziness

>10%

Nausea

>10%

Headache

1-10%

Drowsiness

1-10%

Drug Not Working

1-10%

Anxiety

1-10%

Insomnia

0.1-1%

Fatigue

0.1-1%

ZIPRASIDONE

Drug Not Working

>10%

Weight Gain

1-10%

Anxiety

1-10%

Insomnia

1-10%

Depression

1-10%

Drowsiness

1-10%

Fatigue

1-10%

Tremor

1-10%

FDA Warnings

Lumateperone

No specific warnings

ZIPRASIDONE

5 WARNINGS AND PRECAUTIONS Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse reactions (e
3) Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone
4) Neuroleptic Malignant Syndrome (NMS) : Potentially fatal symptom complex has been reported with antipsychotic drugs
DRESS and other Severe Cutaneous Adverse Reactions (SCAR) are sometimes fatal

Clinical Trial Data

No head-to-head clinical studies found for Lumateperone vs ZIPRASIDONE.

Lumateperone vs ZIPRASIDONE: What You Should Know

Key Differences

Safety Considerations

ZIPRASIDONE carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.